RE:RE:The issue of the safe use of higher doses of vaccinia virus The issue of the safe use of higher doses of vaccina virus is described in collaboration announcement of Signa Technologies and Kalivir Immunotherapeutics for Signa's drug TPOXX, which is a powerful antiviral drug to vaccinia. The collaboration's purpose is to work towards achieving the safe use of vaccinia virus (VV) vectors at higher doses and to bring levels of assurance to physicians, regulators, and especially patients receiving this virus since the vaccina virus is the cow smallpox virus that could potentially revert to its infectious wild state at high doses levels.
In seperate news involving CAR-T therapy in combination with oncolytic virus, a pre-clinical animal study conducted by the Mayo Clinic tested the effects of an oncolytic vesicular stomatitis virus (VSV) and pelareorep alongside CAR-T and found that those mice that received VSV experienced a reduction in the number of circulating CAR-T cells, which was a negative result. Further analysis showed that the type I interferon released upon VSV infection of tumors promoted T-cell death and increased the expression of several inhibitory receptors of the CAR-T cells.
In contrast, loading the CAR-T cells with pelareorep produced synergistic anti-tumor effects. Of the seven mice treated with the regimen, four were still alive at the end of the study. Only one of the seven mice that got CAR-T therapy alone survived. The researchers observed even better results in mice that received a pelareorep booster shot eight days after the combo therapy. All seven mice in that group lived through the entire study period.